Wei‐Yin Wu

METTL14-dependent N6-methyladenosine modification of FGF16 participates in IGFBP5 deficiency-enhanced angiogenesis.

A-FGF16 axis may offer novel therapeutic strategies for ischemic disease.

METTL14-dependent N6-methyladenosine modification of FGF16 participates in IGFBP5 deficiency-enhanced angiogenesis

Abstract N 6 -methyladenosine (m 6 A) RNA modification plays critical roles in physiological and pathological processes. Our prior study demonstrated that IGFBP5 expression is upregulated in the ischemic limb, whereas endothelial-specific IGFBP5 knockout (Igfbp5 EKO ) protects ag...